NASDAQ: COYA - Coya Therapeutics, Inc.

Yield per half year: -29.1%
Sector: Healthcare

Share chart Coya Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis.

More details
The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.000695
EV/EBITDA 12.55
IPO date 2022-12-29
ISIN US22407B1089
Industry Biotechnology
P/BV -5.62
P/S 12.11
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.006
Сайт https://www.coyatherapeutics.com
Цена ао 8.85
Число акций ао 0.01016 млрд
Change price per day: +3.75% (6.588)
Change price per week: +8.84% (6.28)
Change price per month: +17.44% (5.82)
Change price per 3 month: +5.15% (6.5)
Change price per half year: -29.1% (9.64)
Change price per year: +102.22% (3.38)
Change price per 3 year: 0% (6.835)
Change price per 5 year: 0% (6.835)
Change price per 10 year: 0% (6.835)
Change price per year to date: +69.18% (4.04)
All parameters

Underestimation

Title Value Grade
P/S 12.11 1
P/BV 2.04 7
P/E 0 0
EV/EBITDA -5.46 0
Total: 4.75

Efficiency

Title Value Grade
ROA, % -19.35 0
ROE, % -22.41 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.77 10
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 955.08 10
Yield EPS, % 938.19 10
Total: 8
More

Institutions Volume Share, %
Greenlight Capital, Inc. 1274026 8.72
AIGH Capital Management LLC 1031977 7.07
CM Management, LLC 100000 0.68
Vanguard Group Inc 97152 0.67
Worth Venture Partners, LLC 92667 0.63
Geode Capital Management, LLC 92465 0.63
Prelude Capital Management LLC 35770 0.24
Blackrock Inc. 21775 0.15
Potomac Capital Management, Inc. 21101 0.14
Citadel Advisors Llc 16592 0.11

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.02048 11.903735012508 1.54048



Head Job title Payment Year of birth
Dr. Howard Berman Ph.D. Chairman & CEO 833.75k 1974 (50 years)
Mr. David S. Snyder CFO & COO 610.94k 1960 (64 years)
Dr. Fred Grossman D.O., FAPA President & Chief Medical Officer 610.63k 1962 (62 years)
Dr. Gregory MacMichael Ph.D. Chief Technical Officer N/A 1956 (68 years)
Dr. Michelle Frazier Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Aaron Thome Ph.D. Head of Neuroinflammation Platform N/A
Dr. Arun Swaminathan Ph.D. Chief Business Development Officer N/A

Address: United States, Houston. TX, 5850 San Felipe Street - open in Google maps, open in Yandex maps
Website: https://www.coyatherapeutics.com